The Role of Resveratrol Administration in Human Obesity.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
22 Apr 2021
Historique:
received: 06 04 2021
revised: 19 04 2021
accepted: 20 04 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 29 5 2021
Statut: epublish

Résumé

Obesity is a widespread disease that is associated with numerous and serious comorbidities. These include metabolic syndrome, diabetes mellitus, cardiovascular-cerebrovascular disease, hypertension, obstructive sleep apnea syndrome, cancer, and sexual and hormonal disorders. The treatment of obesity has therefore become a goal of great clinical and social relevance. Among the therapeutic strategies against obesity, resveratrol has aroused great interest. This polyphenol has anticancer and antioxidant properties and cytoprotective and anti-inflammatory effects. Other favorable effects attributed to resveratrol are anti-lipid, anti-aging, anti-bacterial, anti-viral, and neuroprotective actions. Administration of resveratrol appears to improve the metabolic profile in obese and/or insulin-resistant patients. This article aims to review the main results of clinical studies evaluating the effects of administering resveratrol alone in overweight/obese patients.

Identifiants

pubmed: 33921991
pii: ijms22094362
doi: 10.3390/ijms22094362
pmc: PMC8122246
pii:
doi:

Substances chimiques

Anti-Obesity Agents 0
Antioxidants 0
Resveratrol Q369O8926L

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Arterioscler Thromb Vasc Biol. 2013 Dec;33(12):2895-901
pubmed: 24072699
J Hypertens. 2013 Sep;31(9):1819-27
pubmed: 23743811
Nature. 2003 Sep 11;425(6954):191-6
pubmed: 12939617
Foods. 2020 Mar 14;9(3):
pubmed: 32183376
Diabetes Obes Metab. 2018 Jul;20(7):1793-1797
pubmed: 29484808
Med Res Rev. 2019 Sep;39(5):1851-1891
pubmed: 30741437
Molecules. 2014 Nov 14;19(11):18632-55
pubmed: 25405284
Nutr Res Pract. 2012 Dec;6(6):499-504
pubmed: 23346299
Cell Metab. 2011 Nov 2;14(5):612-22
pubmed: 22055504
Exp Gerontol. 2014 Sep;57:181-7
pubmed: 24866496
Nutrients. 2020 Sep 28;12(10):
pubmed: 32998364
J Clin Transl Res. 2018 Dec 07;4(2):122-135
pubmed: 30873501
Eur J Nutr. 2015 Jun;54(4):569-79
pubmed: 25030245
Diabet Med. 2013 Oct;30(10):1214-8
pubmed: 23663119
Eur J Endocrinol. 2020 Jan;182(1):G1-G32
pubmed: 31855556
Cell. 2006 Dec 15;127(6):1109-22
pubmed: 17112576
J Gerontol A Biol Sci Med Sci. 2012 Dec;67(12):1307-12
pubmed: 22219517
Am J Clin Nutr. 2020 Oct 1;112(4):1029-1038
pubmed: 32492138
Lipids Health Dis. 2013 Feb 04;12:8
pubmed: 23374859
Clin Nutr ESPEN. 2021 Feb;41:59-67
pubmed: 33487308
Mol Nutr Food Res. 2012 Oct;56(10):1559-68
pubmed: 22945685
Crit Rev Food Sci Nutr. 2020;60(3):375-390
pubmed: 30421960
J Nutr Biochem. 2012 Jul;23(7):829-37
pubmed: 21852083
J Cell Commun Signal. 2014 Dec;8(4):385-91
pubmed: 25387453
J Med Food. 2009 Feb;12(1):100-8
pubmed: 19298202
Trends Endocrinol Metab. 2009 Sep;20(7):325-31
pubmed: 19713122
Metab Syndr Relat Disord. 2016 Sep;14(7):323-33
pubmed: 27379440
Diabetes. 2013 Apr;62(4):1186-95
pubmed: 23193181
Nutrition. 2013 Nov-Dec;29(11-12):1374-80
pubmed: 24012391
Oxid Med Cell Longev. 2021 Jan 31;2021:4593496
pubmed: 33603946
Int J Obes (Lond). 2014 Mar;38(3):470-3
pubmed: 23958793
Ann N Y Acad Sci. 2011 Jan;1215:9-15
pubmed: 21261636
Life Sci. 2020 Sep 1;256:117962
pubmed: 32534040
Cell Mol Life Sci. 2015 Apr;72(8):1473-88
pubmed: 25548801
J Clin Med. 2019 Apr 25;8(4):
pubmed: 31027257
Obesity (Silver Spring). 2020 Sep;28(9):1726-1735
pubmed: 32741148
PLoS One. 2015 Mar 19;10(3):e0118393
pubmed: 25790328
Cell Metab. 2012 May 2;15(5):675-90
pubmed: 22560220
PLoS One. 2014 Jun 10;9(6):e98897
pubmed: 24915004
Biochem Pharmacol. 2009 Mar 15;77(6):1053-63
pubmed: 19100718
Mol Nutr Food Res. 2011 Aug;55(8):1129-41
pubmed: 21688389
Nutr Metab Cardiovasc Dis. 2011 Nov;21(11):851-6
pubmed: 20674311
Science. 1997 Jan 10;275(5297):218-20
pubmed: 8985016
Nutr Res Rev. 2009 Dec;22(2):111-7
pubmed: 19772694

Auteurs

Laura M Mongioì (LM)

Department of Clinical and Experimental Medicine, University of Catania, Policlinico "G. Rodolico", Via S. Sofia 78, 95123 Catania, Italy.

Sandro La Vignera (S)

Department of Clinical and Experimental Medicine, University of Catania, Policlinico "G. Rodolico", Via S. Sofia 78, 95123 Catania, Italy.

Rossella Cannarella (R)

Department of Clinical and Experimental Medicine, University of Catania, Policlinico "G. Rodolico", Via S. Sofia 78, 95123 Catania, Italy.

Laura Cimino (L)

Department of Clinical and Experimental Medicine, University of Catania, Policlinico "G. Rodolico", Via S. Sofia 78, 95123 Catania, Italy.

Michele Compagnone (M)

Department of Clinical and Experimental Medicine, University of Catania, Policlinico "G. Rodolico", Via S. Sofia 78, 95123 Catania, Italy.

Rosita A Condorelli (RA)

Department of Clinical and Experimental Medicine, University of Catania, Policlinico "G. Rodolico", Via S. Sofia 78, 95123 Catania, Italy.

Aldo E Calogero (AE)

Department of Clinical and Experimental Medicine, University of Catania, Policlinico "G. Rodolico", Via S. Sofia 78, 95123 Catania, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH